Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy
Status:
Terminated
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
RA (Rheuatoid arthritis) is a multisystem disease that mainly involves joints resulting in
destructive arthritis if not treated rapidly. Inspite of various advances in field of early
diagnosis and treatment of RA, there is still a need for better understanding of the efficacy
and safety of various combinations of conventional DMARDS, and to rank them in order
accordingly, so as to give a clearer vision for further management of RA once MTX monotherapy
fails, so as to achieve remission as soon as possible. The study will be conducted at the
Department of Clinical Immunology, JIPMER (Jawaharlal Institute of Postgraduate Medical
Education & Research). patients who fail methotrexate monotherapy will be randomised to 2
treatment arms - either a combination of Sulfasalazine (SSZ), Hydroxychloroquine (HCQ) and
Methotrexate (MTX) or Leflunomide (LEF), Hydroxychloroquine (HCQ) and Methotrexate (MTX)
Phase:
Phase 3
Details
Lead Sponsor:
Jawaharlal Institute of Postgraduate Medical Education & Research